Clinical Indications for Desmopressin (DDAVP)
Desmopressin is FDA-approved for central diabetes insipidus, primary nocturnal enuresis, mild type I von Willebrand disease, and mild hemophilia A with factor VIII levels ≥5% of normal. 1
Primary FDA-Approved Indications
Central Diabetes Insipidus
Desmopressin serves as antidiuretic replacement therapy for central diabetes insipidus and temporary polyuria/polydipsia following head trauma or pituitary surgery 1. It is ineffective for nephrogenic diabetes insipidus 1. The drug acts as a synthetic analog of vasopressin, selectively targeting V2 receptors to promote renal water reabsorption 2.
Primary Nocturnal Enuresis
For children with bedwetting, desmopressin is most effective in those with nocturnal polyuria (>130% of expected bladder capacity) and normal bladder function (maximum voided volume >70% of expected capacity) 3. The drug provides grade Ia evidence-based therapy, with approximately 30% achieving complete response and 40% partial response 3.
Key predictive factors for complete response include:
- Fewer than 17 wet nights per month (sensitivity 92.3%, specificity 47.6%) 4
- Single bedwetting episode per night rather than multiple 4
Critical safety consideration: Oral formulations are strongly preferred over nasal spray due to higher risk of water intoxication and hyponatremia with intranasal administration 3. Fluid restriction is mandatory—limit evening intake to ≤200 mL (6 ounces) with no drinking until morning 3.
Bleeding Disorders
Von Willebrand Disease and Hemophilia A
Desmopressin is indicated for mild type I von Willebrand disease and mild hemophilia A (factor VIII ≥5% of normal) 5. It promotes release of von Willebrand factor and factor VIII from endothelium 5. The drug increases factor VIII levels by 2-3 fold, with peak effect at 30-60 minutes after infusion 6.
Important limitation: Desmopressin does not increase factor VIII in severe hemophilia A due to lack of available stores 6. Tachyphylaxis occurs after three consecutive doses due to storage pool depletion 6.
Perioperative Use in Bleeding Disorders
For patients with von Willebrand disease, hemophilia A, or platelet hemostatic disorders, preoperative desmopressin (0.3 μg/kg IV over 20 minutes) may be useful before cardiac surgery 5, 6. However, prophylactic use in patients without platelet defects is NOT recommended—three meta-analyses show no benefit, and Society of Thoracic Surgeons/Society of Cardiovascular Anesthesiologists guidelines explicitly advise against it 5.
Off-Label Uses with Evidence
Uremic Platelet Dysfunction
Desmopressin dramatically shortens bleeding time in uremia and can stop hemorrhages or prevent bleeding before surgical procedures 7. This represents one of the most established off-label indications 8.
Acquired Platelet Dysfunction
The drug may benefit patients with platelet dysfunction from cardiopulmonary bypass or recent antiplatelet therapy before cardiac surgery, though evidence certainty is low 9. For intracranial hemorrhage in patients on antiplatelet drugs, desmopressin shows feasibility and safety but requires confirmatory data 9.
Critical Safety Warnings
Absolute contraindications: 1
- Known hypersensitivity to desmopressin
- Moderate to severe renal impairment (creatinine clearance <50 mL/min)
- Hyponatremia or history of hyponatremia
- Habitual or psychogenic polydipsia
Hyponatremia warning signs to monitor: 1
- Headache, nausea/vomiting, weight gain
- Restlessness, fatigue, lethargy, disorientation
- Decreased serum sodium, depressed reflexes
- Muscle weakness, spasms, or cramps
- Severe: seizures, coma, respiratory arrest
Pediatric and geriatric patients require downward fluid adjustment and closer monitoring 1. Serum electrolytes should be monitored during intercurrent illnesses affecting hydration 10.
Dosing by Indication
Enuresis: 0.2-0.4 mg oral tablets or 120-240 μg oral melt, taken 1 hour (tablets) or 30-60 minutes (melt) before bedtime 3. Dose is not weight-based 3.
Hemophilia/von Willebrand disease: 0.3 μg/kg IV over 20 minutes 6. Can be given intranasally or subcutaneously, though IV provides most consistent response 7.
Central diabetes insipidus: Dosing per FDA label for antidiuretic replacement 1.